发明名称 |
PD-L1 (PROGRAMMED DEATH-LIGAND 1) ANTIBODIES |
摘要 |
The present disclosure relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1 ), useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics. Said antibodies have specific variable chain sequences. According to the experimental results, they demonstrate superior association rates that translate into better in vivo activity and T cell response to a tumor cells. |
申请公布号 |
WO2017034916(A1) |
申请公布日期 |
2017.03.02 |
申请号 |
WO2016US47528 |
申请日期 |
2016.08.18 |
申请人 |
ELI LILLY AND COMPANY |
发明人 |
LI, Yiwen;LUDWIG, Dale Lincoln;MOLKENTHIN, Vera;SHEN, Juqun;SNAVELY, Marshall Davenport |
分类号 |
A61K39/395;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|